Video

Dr Zahra Mahmoudjafari Previews CAR T Therapies Coming Down the Pipeline

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

Zahra Mahmoudjafari, PharmD, BCOP, clinical pharmacy manager at the University of Kansas Health System, catalogues the chimeric antigen receptor T-cell (CAR T) therapies that are coming down the pipeline.

Transcript

What CAR T therapies do you see coming down the pipeline and how do they differ from each other?

That's a loaded question; there's a lot. For the currently approved products, we're learning to use them earlier in lines of care. For the diffuse large B-cell lymphoma population, those indications, and second-line therapy should be coming anytime in the next week to the next couple of months.

Then, we are looking at expanding indications to larger disease states. Obviously, we've had a lot of great approvals with the multiple myeloma products. That recent approval was just on February 28, so I think myeloma is good for a little bit.

In terms of CAR T specifically, for immune effector cells, the bispecifics are the next thing that we're really excited about. We're also looking at allogeneic CAR T products, which are off the shelf, which would really significantly decrease the manufacturing time that we are challenged with at this point.

Related Videos
Barry Byrne, MD, PhD, Powell Gene Therapy Center at the University of Florida
JC Scott, CEO and president, PCMA
Caspian Oliai, MD, MS, a medical oncologist and hematologist and medical director of the UCLA Bone Marrow Transplantation Stem Cell Processing Center
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Adam Colburn, JD, vice president for congressional affairs, AMCP
Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center
Andrew Kuykendall, MD, Moffitt Cancer Center
Anna Mueller, MD, Mount Sinai
Marc Humbert, MD, PhD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo